THRX Key Statistics, Chart & Performance
The current stock price of THRX is 4.06 USD. In the past month the price increased by 1.75%. In the past year, price decreased by -64.45%.
THRX Latest News, Press Relases and Analysis
THRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.91 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.53B | ||
| MRK | MERCK & CO. INC. | 11.9 | 260.19B | ||
| PFE | PFIZER INC | 8.04 | 146.35B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.16B | ||
| ZTS | ZOETIS INC | 20.22 | 56.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.74 | 23.10B | ||
| VTRS | VIATRIS INC | 4.59 | 12.31B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.24 | 11.56B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.23 | 8.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.64B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.80B |
Related stock screener links
About THRX
Company Profile
Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. The company is headquartered in Cambridge, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-10-07. The company is focused on treating cancer patients through the discovery, development, and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company also focused on tyrosine kinase inhibitors (TKIs), which is rooted in the critical role that tyrosine kinases play in the development of cancer. The company develops pan-variant kinase inhibitors-inhibitors that target cancer-causing and drug resistance mutations in clinically protein kinases. Its product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase for the treatment of GIST, a type of cancer often characterized by oncogenic activation of KIT. The company is also developing THE-349, a selective epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer.
Company Info
THESEUS PHARMACEUTICALS INC
314 Main Street, Suite 04-200
Cambridge MASSACHUSETTS 94080 US
CEO: Michael W. Aguiar
Employees: 38
Phone: 18574009491
THESEUS PHARMACEUTICALS INC / THRX FAQ
What does THESEUS PHARMACEUTICALS INC do?
Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. The company is headquartered in Cambridge, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-10-07. The company is focused on treating cancer patients through the discovery, development, and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company also focused on tyrosine kinase inhibitors (TKIs), which is rooted in the critical role that tyrosine kinases play in the development of cancer. The company develops pan-variant kinase inhibitors-inhibitors that target cancer-causing and drug resistance mutations in clinically protein kinases. Its product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase for the treatment of GIST, a type of cancer often characterized by oncogenic activation of KIT. The company is also developing THE-349, a selective epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer.
Can you provide the latest stock price for THESEUS PHARMACEUTICALS INC?
The current stock price of THRX is 4.06 USD.
Does THESEUS PHARMACEUTICALS INC pay dividends?
THRX does not pay a dividend.
How is the ChartMill rating for THESEUS PHARMACEUTICALS INC?
THRX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of THESEUS PHARMACEUTICALS INC (THRX) based on its PE ratio?
THESEUS PHARMACEUTICALS INC (THRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.34).
Can you provide the upcoming earnings date for THESEUS PHARMACEUTICALS INC?
THESEUS PHARMACEUTICALS INC (THRX) will report earnings on 2024-03-07, after the market close.
THRX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to THRX. When comparing the yearly performance of all stocks, THRX is a bad performer in the overall market: 86.76% of all stocks are doing better.
THRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to THRX. THRX has a great financial health rating, but its profitability evaluates not so good.
THRX Financial Highlights
Over the last trailing twelve months THRX reported a non-GAAP Earnings per Share(EPS) of -1.34. The EPS decreased by -12.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.13% | ||
| ROE | -25.22% | ||
| Debt/Equity | 0 |
THRX Forecast & Estimates
9 analysts have analysed THRX and the average price target is 5.36 USD. This implies a price increase of 31.9% is expected in the next year compared to the current price of 4.06.